Novartis

Boston Pharma Doubles Pipeline with 2 Deals with Novartis and GSK
Boston Pharma Doubles Pipeline with 2 Deals with Novartis and GSK
BioSpace
Boston Pharmaceuticals
GSK
Novartis
Flag link:
Roche, Novartis grab FDA OK for new version of aging blockbuster Xolair
Roche, Novartis grab FDA OK for new version of aging blockbuster Xolair
Fierce Pharma
Roche
Novartis
Xolair
Xolair pen
FDA
Flag link:
Vas Narasimhan, Novartis CEO, explains reasons behind 2,100 jobs cut
Vas Narasimhan, Novartis CEO, explains reasons behind 2,100 jobs cut
GoinPharma
Novartis
layoffs
Vas Narasimhan
Pharma CEOs
Flag link:
Three new drugs will compete fiercely to revolutionize migraine treatment — with identical $6,900 price tags
Three new drugs will compete fiercely to revolutionize migraine treatment — with identical $6,900 price tags
Marketwatch
migraines
Eli Lilly
Emgality
Teva Pharmaceutical
Ajovy
Amgen
Novartis
Aimovig
Flag link:
Novartis signs manufacturing deal for Kymriah in China
Novartis signs manufacturing deal for Kymriah in China
BioCentury
Novartis
Kymriah
China
drug manufacturing
Flag link:
Mylan and Novartis to FDA: Where are the Suffixes?
Mylan and Novartis to FDA: Where are the Suffixes?
RAPS.org
Mylan Labs
Novartis
drug names
biosimilars
biologics
Flag link:
Novartis to cut 2,200 jobs in Switzerland to boost profits
Novartis to cut 2,200 jobs in Switzerland to boost profits
Pharmaforum
Novartis
layoffs
Switzerland
Flag link:
Novartis, Bayer consider appeal as court says Avastin can be used in AMD
Novartis, Bayer consider appeal as court says Avastin can be used in AMD
Pharmaforum
UK
Roche
Avastin
wet age-related macular degeneration
Novartis
Bayer
Flag link:
Novartis plans to file for new Lucentis indication in ROP
Novartis plans to file for new Lucentis indication in ROP
Pharmaceutical Business Review
Novartis
Lucentis
ROP
retinopathy of prematurity
Flag link:
Spark/Novartis eye gene therapy nears EU market – but at what price?
Spark/Novartis eye gene therapy nears EU market – but at what price?
Pharmaforum
Spark Therapeutics
Novartis
Luxturna
gene therapy
Europe
Flag link:
Ex-Novartis Chief Joins uBiome to Help Launch Discovery and Development Business
Ex-Novartis Chief Joins uBiome to Help Launch Discovery and Development Business
CP Wire
uBiome
Joe Jimenez
microbiome
Novartis
Flag link:
NICE rejects Novartis’ CAR-T in adult lymphoma
NICE rejects Novartis’ CAR-T in adult lymphoma
Pharmaforum
NICE
UK
Novartis
CAR-T
Kymriah
NHS
diffuse large B-cell lymphoma
Flag link:
Novartis links bonuses to ethics in bid to rebuild reputation
Novartis links bonuses to ethics in bid to rebuild reputation
Reuters
Novartis
ethics
bonuses
compensation
Flag link:
Pfizer, Glaxo, Novo, Novartis plants unfazed by hurricane, resume production
Pfizer, Glaxo, Novo, Novartis plants unfazed by hurricane, resume production
Fierce Pharma
Pfizer
GSK
Novo Nordisk
Novartis
drug manufacturing
hurricanes
Flag link:
UCSD researchers identify mechanism, target in NASH
UCSD researchers identify mechanism, target in NASH
BioCentury
NASH
Novartis
Flag link:
Amgen, Sandoz begin biosimilar trial with top-selling Enbrel at stake
Amgen, Sandoz begin biosimilar trial with top-selling Enbrel at stake
Biopharma Dive
Amgen
Sandoz
Enbrel
biosimilars
Novartis
Flag link:
Novartis, Novo, Glaxo and others hunker down as hurricane sweeps in
Novartis, Novo, Glaxo and others hunker down as hurricane sweeps in
Fierce Pharma
Novartis
Novo Nordisk
Pfizer
GSK
hurricanes
Flag link:
The Curious Case Of Gleevec Pricing
The Curious Case Of Gleevec Pricing
Forbes
drug pricing
Gleevec
Novartis
Flag link:
Novartis makes it official: Alcon is moving its HQ from Texas to Geneva ahead of a spinoff
Novartis makes it official: Alcon is moving its HQ from Texas to Geneva ahead of a spinoff
Endpoints
Novartis
Alcon
Geneva
Texas
Flag link:
Mylan Strikes $463 Million Deal With Novartis for CF Product Line
Mylan Strikes $463 Million Deal With Novartis for CF Product Line
BioSpace
Mylan Labs
Novartis
cystic fibrosis
Flag link:

Pages